Technical Analysis for MDFZF - Medifocus Inc

Grade Last Price % Change Price Change
grade F 0.0043 -14.00% -0.0007
MDFZF closed down 14.0 percent on Tuesday, August 20, 2019, on 78 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical MDFZF trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -14.00%

Older signals for MDFZF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is a leader in the use of focused microwave energy to treat cancer and other tumors. It owns two fully developed technology platforms with comprehensive US and international patent protection: (1) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The U.S. FDA approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (?BPH?) was developed based on the Endo-thermotherapy and is currently generating revenue, and (2) The Adaptive Phased Array (APA) Microwave Focusing Platform-invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company?s APA 1000 Breast Cancer Treatment System, developed from the APA technology platform has received approval from the U.S. FDA and Health Canada to conduct the pivotal Phase III clinical trials. The Company believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers.
Medicine Health RTT Medical Specialties Cancer Microwave Fda Tumor Food And Drug Administration Radiation Therapy Technology Platforms Catheter Tumors Benign Prostatic Hyperplasia Bph Mit Thermotherapy Treatment Of Benign Prostatic Hyperplasia
Is MDFZF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 0.0514
52 Week Low 0.0023
Average Volume 196,019
200-Day Moving Average 0.0243
50-Day Moving Average 0.0194
20-Day Moving Average 0.0134
10-Day Moving Average 0.0106
Average True Range 0.0041
ADX 28.28
+DI 17.851
-DI 46.6205
Chandelier Exit (Long, 3 ATRs ) 0.0078
Chandelier Exit (Short, 3 ATRs ) 0.0146
Upper Bollinger Band 0.0222
Lower Bollinger Band 0.0046
Percent B (%b) -0.02
BandWidth 131.343284
MACD Line -0.0037
MACD Signal Line -0.0027
MACD Histogram -0.0011
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0063
Resistance 3 (R3) 0.0060 0.0052 0.0059
Resistance 2 (R2) 0.0052 0.0047 0.0053 0.0058
Resistance 1 (R1) 0.0047 0.0044 0.0050 0.0050 0.0057
Pivot Point 0.0039 0.0039 0.0040 0.0040 0.0039
Support 1 (S1) 0.0034 0.0034 0.0037 0.0037 0.0029
Support 2 (S2) 0.0026 0.0031 0.0027 0.0028
Support 3 (S3) 0.0021 0.0026 0.0027
Support 4 (S4) 0.0024